{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T22:41:44Z","timestamp":1768084904696,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Roche-Chugai pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The Flare Assessment in RA (FLARE-RA) self-administered questionnaire aims to identify patients who had flare in the interval between two consultations. This study aimed to establish a threshold for FLARE-RA score to identify RA flare.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The Tocilizumab SubCutAneous study evaluated the efficacy and safety of s.c. tocilizumab (TCZ) to patients with active RA. Disease activity was assessed with the DAS28ESR at baseline and at week 2 (W2), W4, W12 and W24. The FLARE-RA questionnaire was administered at W12 and W24. Patient satisfaction, assessed at baseline and W24 with the Patient Acceptable Symptom State (PASS), was used as a surrogate marker of no flare. A correlation was sought between the FLARE-RA score at W12 and W24 and the area under the receiver operating characteristic (ROC) curve (AUC) for monthly DAS28ESR. The optimal FLARE-RA cut-off below which patient satisfaction reached the PASS was explored with an ROC curve.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 139 patients were included (mean age 57.3\u2009\u00b1\u200913.8\u2009years, 74.1% women, mean RA duration 10.8\u2009\u00b1\u20099.2\u2009years, mean DAS28ESR 5.8\u2009\u00b1\u20091.1). The correlation between the FLARE-RA score and DAS28ESR AUC was moderate at all times: \u03c1 = 0.41 at W12 (P\u00a0&amp;lt; 0.0001) and 0.51 at W24 (P\u00a0&amp;lt; 0.0001). The optimal cut-off for the FLARE-RA score to identify absence of flare (i.e. an acceptable situation based on the PASS) was 2.3 with an AUC of 0.81.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>FLARE-RA and DAS28ESR assessment differ; we propose a FLARE-RA cut-off of 2.3, below which the situation (i.e. without flare) is acceptable for patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keab261","type":"journal-article","created":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T19:14:12Z","timestamp":1617131652000},"page":"337-344","source":"Crossref","is-referenced-by-count":6,"title":["Cut-off value to identify a flare using the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire: analysis of the TOSCA study"],"prefix":"10.1093","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8708-9324","authenticated-orcid":false,"given":"Krystel","family":"Aouad","sequence":"first","affiliation":[{"name":"Rheumatology Department, Piti\u00e9 Salp\u00eatri\u00e8re hospital, Sorbonne Universit\u00e9 \u2013 Assistance Publique H\u00f4pitaux de Paris, Paris, France"},{"name":"Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Gaudin","sequence":"additional","affiliation":[{"name":"Rheumatology Department, H\u00f4pital Sud, A Michallon, Echirolles, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Vittecoq","sequence":"additional","affiliation":[{"name":"Rheumatology & CIC-CRB 1404 Department, Rouen University Hospital and Normandie University, UNIROUEN, Rouen, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacques","family":"Morel","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU and University of Montpellier, Montpellier, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Berthelot","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Nantes, Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Senbel","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Sainte Marguerite Hospital, Marseille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Schaeverbeke","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU Bordeaux, Universit\u00e9 V Segalen, Bordeaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Liot\u00e9","sequence":"additional","affiliation":[{"name":"Rhumatology Department, CHU Lariboisi\u00e8re, Centre Viggo Petersen, Universit\u00e9 de Paris-AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9-Marc","family":"Flipo","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Universit\u00e9 de Lille, CHU Lille, Lille, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandrine","family":"Pinta","sequence":"additional","affiliation":[{"name":"ROCHE, Boulogne Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Guillemin","sequence":"additional","affiliation":[{"name":"Inserm CIC 1433, Epid\u00e9miologie clinique, CHRU Nancy, Nancy, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8845-4274","authenticated-orcid":false,"given":"Bruno","family":"Fautrel","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Piti\u00e9 Salp\u00eatri\u00e8re hospital, Sorbonne Universit\u00e9 \u2013 Assistance Publique H\u00f4pitaux de Paris, Paris, France"},{"name":"Sorbonne University\u2014INSERM, U1136-6, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"2022010903445349600_keab261-B1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.11481","article-title":"Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission","volume":"50","author":"Molenaar","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.3899\/jrheum.090369","article-title":"Developing a standardized definition for disease \u201cflare\u201d in rheumatoid arthritis (OMERACT 9 Special Interest Group)","volume":"36","author":"Bingham","year":"2009","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B5","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1136\/annrheumdis-2012-202281","article-title":"Construct and criterion validity of several proposed DAS28-based rheumatoid arthritis flare criteria: an OMERACT cohort validation study","volume":"72","author":"van der Maas","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.3899\/jrheum.110400","article-title":"Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group","volume":"38","author":"Alten","year":"2011","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B7","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/art.20350","article-title":"The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis","volume":"50","author":"Welsing","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B8","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-015-0730-2","article-title":"Disease flares in rheumatoid arthritis are associated with joint damage progression and disability: 10-year results from the BeSt study","volume":"17","author":"Markusse","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2022010903445349600_keab261-B9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1136\/annrheumdis-2014-206411","article-title":"The role of rheumatoid arthritis (RA) flare and cumulative burden of RA severity in the risk of cardiovascular disease","volume":"75","author":"Myasoedova","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/rheumatology\/keq455","article-title":"\u2018I\u2019m hurting, I want to kill myself\u2019: rheumatoid arthritis flare is more than a high joint count\u2013an international patient perspective on flare where medical help is sought","volume":"51","author":"Hewlett","year":"2012","journal-title":"Rheumatol"},{"key":"2022010903445349600_keab261-B11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1136\/annrheumdis-2011-201201","article-title":"Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus","volume":"71","author":"Bartlett","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1136\/ard.2011.150656","article-title":"A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: the \u201cFLARE\u201d instrument","volume":"71","author":"Berthelot","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/art.39850","article-title":"Validation of FLARE-RA, a Self-Administered Tool to Detect Recent or Current Rheumatoid Arthritis Flare","volume":"69","author":"Fautrel","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2022010903445349600_keab261-B14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10067-019-04755-3","article-title":"The American English version of the validated French Flare Assessment in RA Questionnaire (FLARE-RA)","volume":"39","author":"Barroso","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2022010903445349600_keab261-B15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10067-014-2849-y","article-title":"Patient self-assessment of flare in rheumatoid arthritis: criterion and concurrent validity of the Flare instrument","volume":"35","author":"de Thurah","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022010903445349600_keab261-B16","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10067-014-2848-z","article-title":"Patient-self assessment of flare in rheumatoid arthritis: translation and reliability of the Flare instrument","volume":"35","author":"Maribo","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2022010903445349600_keab261-B17","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4081\/reumatismo.2020.1230","article-title":"Translation and cross-cultural adaptation into Italian of the self-administered FLARE-RA questionnaire for rheumatoid arthritis","volume":"72","author":"Ughi","year":"2020","journal-title":"Reumatismo"},{"key":"2022010903445349600_keab261-B18"},{"key":"2022010903445349600_keab261-B19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B20","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"2022010903445349600_keab261-B21","first-page":"iii40","article-title":"Minimal clinically important improvement\/difference (MCII\/MCID) and patient acceptable symptom state (PASS): what do these concepts mean?","volume":"66","author":"Kvien","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2022010903445349600_keab261-B22","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/art.22110","article-title":"Feeling good rather than feeling better matters more to patients","volume":"55","author":"Tubach","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B23"},{"key":"2022010903445349600_keab261-B24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3899\/jrheum.131252","article-title":"Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA flare Workshop","volume":"41","author":"Bykerk","year":"2014","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B25","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3899\/jrheum.161145","article-title":"Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report","volume":"44","author":"Bartlett","year":"2017","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B26","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/acr.20178","article-title":"Reliability of patient self-evaluation of swollen and tender joints in rheumatoid arthritis: a comparison study with ultrasonography, physician, and nurse assessments","volume":"62","author":"Cheung","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2022010903445349600_keab261-B27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/acr.20066","article-title":"RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety seconds","volume":"62","author":"Pincus","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2022010903445349600_keab261-B28","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/acr.20481","article-title":"RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol","volume":"63","author":"Pincus","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2022010903445349600_keab261-B29","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3899\/jrheum.080182","article-title":"RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories","volume":"35","author":"Pincus","year":"2008","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B30","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/art.1780380612","article-title":"A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity","volume":"38","author":"Stucki","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B31","first-page":"1294","article-title":"Patient-centered rheumatoid arthritis disease activity assessment by a modified RADAI","volume":"35","author":"Leeb","year":"2008","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B32","first-page":"2410","article-title":"A composite disease activity scale for clinical practice, observational studies, and clinical trials: the patient activity scale (PAS\/PAS-II)","volume":"32","author":"Wolfe","year":"2005","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B33","first-page":"186","article-title":"Psychometric properties of an index of three patient reported outcome (PRO) measures, termed the CLinical ARthritis Activity (PRO-CLARA) in patients with rheumatoid arthritis. The NEW INDICES study","volume":"28","author":"Salaffi","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2022010903445349600_keab261-B34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2019.09.004","article-title":"Definition and construct validation of clinically relevant cutoffs on the Flare Assessment in Rheumatoid Arthritis (FLARE-RA) questionnaire","volume":"50","author":"Myasoedova","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2022010903445349600_keab261-B35","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3899\/jrheum.141169","article-title":"Feasibility and Domain Validation of Rheumatoid Arthritis (RA) Flare Core Domain Set: report of the OMERACT 2014 RA Flare Group Plenary","volume":"42","author":"Bartlett","year":"2015","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/art.22469","article-title":"Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing spondylitis","volume":"57","author":"Maksymowych","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2022010903445349600_keab261-B37","first-page":"1188","article-title":"Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders","volume":"34","author":"Tubach","year":"2007","journal-title":"J Rheumatol"},{"key":"2022010903445349600_keab261-B38","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/0895-4356(93)90142-N","article-title":"Cross-cultural adaptation of health-related quality of life measures: literature review and proposed guidelines","volume":"46","author":"Guillemin","year":"1993","journal-title":"J Clin Epidemiol"},{"key":"2022010903445349600_keab261-B39","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jclinepi.2013.07.013","article-title":"Cross-cultural adaptation of the Health Education Impact Questionnaire: experimental study showed expert committee, not back-translation, added value","volume":"68","author":"Epstein","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"2022010903445349600_keab261-B40","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/rheumatology\/31.8.519","article-title":"Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients","volume":"31","author":"van der Heijde","year":"1992","journal-title":"Br J Rheumatol"},{"key":"2022010903445349600_keab261-B41","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/rheumatology\/25.1.44","article-title":"Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression","volume":"25","author":"Dawes","year":"1986","journal-title":"Br J Rheumatol"},{"key":"2022010903445349600_keab261-B42","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1111\/1756-185X.13110","article-title":"Performances of Clinical Disease Activity Index (CDAI) and Simplified Disease Activity Index (SDAI) appear to be better than the gold standard Disease Assessment Score (DAS-28-CRP) to assess rheumatoid arthritis patients","volume":"21","author":"Dhaon","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"2022010903445349600_keab261-B43","first-page":"doi:10.1002\/acr.24163","article-title":"Outcomes reported in prospective long-term observational studies and registries of patients with rheumatoid arthritis worldwide: an OMERACT systematic review","author":"Lopez-Olivo","year":"2020","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keab261\/37061730\/keab261.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/337\/41929191\/keab261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/61\/1\/337\/41929191\/keab261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T03:46:23Z","timestamp":1641699983000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/61\/1\/337\/6206786"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,31]]},"published-print":{"date-parts":[[2021,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keab261","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,31]]}}}